Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性

doi:10.11904/j.issn.1002-3070.2019.02.005

实用肿瘤学杂志 ›› 2019, Vol. 33 ›› Issue (2): 122-127.doi: 10.11904/j.issn.1002-3070.2019.02.005

Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性

白晓斌¹, 霍龙伟², 谢万福¹, 徐高峰¹, 王茂德¹

1.西安交通大学第一附属医院神经外科(西安 710061);
2.榆林市第一医院神经外科

收稿日期:2018-11-02 修回日期:2018-12-21 出版日期:2019-04-20 发布日期:2019-04-25
通讯作者: 王茂德,E-mail:maodewang@163.com
作者简介:白晓斌,男,(1977-),硕士,主治医师,从事神经系统肿瘤临床与基础的研究

Expression of Chk1 in glioblastoma and its association with tumor biological behavior and prognosis survival

BAI Xiaobin¹, HUO Longwei², XIE Wanfu¹, XU Gaofeng¹, WANG Maode¹

1.Department of Neurosurgery, The First Affiliated Hospital of Xi'An Jiaotong University, Xi'An 710061, China;
2.Department of Neurosurgery, The First Hospital of Yulin

Received:2018-11-02 Revised:2018-12-21 Online:2019-04-20 Published:2019-04-25

摘要/Abstract

摘要： 目的研究细胞周期检测点激酶1(Checkpoint kinase 1,Chk1)在胶质母细胞瘤细胞(Glioblastoma,GBM)中的表达及其与GBM细胞增殖、成瘤活性和预后生存的关联性。方法利用TCGA数据库和脑肿瘤分子数据库(Rembrandt)选择和分析GBM中Chk1的表达,并采用Western blot和Real-time PCR等分子生物学技术检测GBM细胞中Chk1的表达水平;通过慢病毒转染siRNA沉默Chk1的表达以探究其对于GBM细胞增殖和成球能力的影响;同时利用免疫组化染色及Rembrandt数据库对Chk1与GBM患者的预后生存关系进行分析。结果 TCGA和Rembrandt数据库分析结果表明Chk1在GBM组织中呈现高表达,同样Western blot和Real-time PCR检测结果显示Chk1在GBM细胞中呈现高表达;慢病毒转染siRNA特异性沉默Chk1能够显著抑制U87细胞的生长(P＜0.01)和成球能力(P＜0.05);预后生存分析结果显示Chk1低表达GBM患者的临床预后显著优于高表达患者(P＜0.001)。结论 Chk1在GBM细胞中过量表达,表达上调能够促进GBM细胞的生长和增殖,并和GBM患者的不良预后相关。

关键词: 胶质母细胞瘤, 细胞周期检测点激酶1, 细胞增殖, 预后

Abstract: Objective The aim of this study was to investigate the expression of cell cycle checkpoint kinase 1(Chk1)gene in glioblastoma cells(GBM)and its correlation with GBM cell proliferation,tumorigenic activity and prognosis. Methods The expression of Chk1 in GBM cells was selected and analyzed by TCGA database and brain tumor molecular database(Rembrandt),and the level of Chk1 expression in GBM cells was detected by molecular biology techniques such as Western blot and Real-Time PCR.The expression of Chk1 was silenced by siRNA to investigate its effect on proliferation and colony-forming ability of GBM cells.The prognosis survival of GBM patients accompanying with Chk1 expression was analyzed by immunohistochemical staining and Rembrandt database. Results The results of TCGA database and Rembrandt showed that Chk1 gene was highly expressed in GBM tissues.Western blot and Real-Time PCR also showed that Chk1 gene was highly expressed in GBM cells.Lentiviral transfection siRNA-specific silencing of Chk1 significantly inhibited proliferation and colony-forming ability of U87 cells(P＜0.01 and P＜0.05).Prognostic survival analysis showed that GBM patients with low expression of Chk1 gene had a significantly better clinical outcome than those of GBM patients with high expression of Chk1 gene(P＜0.001). Conclusion Chk1 gene is overexpressed in GBM cells,up-regulation of Chk1 gene expression can promote the growth and proliferation of GBM cells,and Chk1 gene is associated with poor prognosis in GBM patients.

Key words: Glioblastoma, Chk1, Cell proliferation, Prognosis

中图分类号:

白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.

BAI Xiaobin, HUO Longwei, XIE Wanfu, XU Gaofeng, WANG Maode. Expression of Chk1 in glioblastoma and its association with tumor biological behavior and prognosis survival[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 122-127.

参考文献

1 Qi L,Ding L,Wang S,et al.A network meta-analysis:the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy(RT)[J].Oncotarget,2016,7(42):69002-69013.
2 Signorovitch J,Li N,Ohashi E,et al.Overall survival(Os),quality of life(Qol),and Neurocognitive function(Nf)in recurrent glioblastoma multiforme(Gbm):a systematic literature review[J].Value Health,2015,18(7):433.
3 Furusawa Y,Yamanouchi Y,Iizumi T,et al.Checkpoint kinase 2 is dispensable for regulation of the p53 response but is required for G2/M arrest and cell survival in cells with p53 defects under heat stress[J].Apoptosis,2017,22(10):1225-1234.
4 Gali-Muhtasib H,Kuester D,Mawrin C,et al.Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells[J].Cancer Res,2008,68(14):5609-56018.
5 Alcaraz-Sanabria A,Nieto-Jimenez C,Corrales-Sanchez V,et al.Synthetic lethality interaction between Aurora kinases and CHEK1 inhibitors in ovarian cancer[J].Mol Cancer Ther,2017,16(11):2552-2562.
6 Liu B,Qu J,Xu F,et al.MiR-195 suppresses non-small cell lung cancer by targeting CHEK1[J].Oncotarget,2015,6(11):9445-9456.
7 Lin WY,Brock IW,Connley D,et al.Associations of ATR and CHEK1 single nucleotide polymorphisms with breast cancer[J].PLoS One,2013,8(7):e68578.
8 Kim MK,Min DJ,Wright G,et al.Loss of compensatory pro-survival and anti-apoptotic modulator,IKKepsilon,sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21[J].Oncotarget,2014,5(24):12788-12802.
9 Kim MK,James J,Annunziata CM.Topotecan synergizes with CHEK1(CHK1)inhibitor to induce apoptosis in ovarian cancer cells[J].BMC Cancer,2015,15:196.
10 Bai X,Wang J,Huo L,et al.Serine/Threonine kinase CHEK1-dependent transcriptional regulation of RAD54L promotes proliferation and radio resistance in glioblastoma[J].Transl Oncol,2018,11(1):140-146.
11 Wang J,Cheng P,Pavlyukov MS,et al.Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2[J].J Clin Invest,2017,127(8):3075-3089.
12 Teo M,Martin S,Owusu-Agyemang K,et al.A survival analysis of GBM patients in the West of Scotland pre-and post-introduction of the Stupp regime[J].Br J Neurosurg,2014,28(3):351-355.
13 Duffau H.Glioblastoma in 2017[J].Rev Infirm,2017,66(228):16-18.
14 Sun X,Xiao D,Xu T,et al.miRNA-24-3p promotes cell proliferation and regulates chemosensitivity in head and neck squamous cell carcinoma by targeting CHD5[J].Future Oncol,2016,12(23):2701-2712.
15 Abdel-Fatah TM,Middleton FK,Arora A,et al.Untangling the ATR-CHEK1 network for prognostication,prediction and therapeutic target validation in breast cancer[J].Mol Oncol,2015,9(3):569-585.
16 Matsumoto K,Nagahara T,Okano J,et al.The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases[J].Oncol Rep,2008,20(4):863-872.
17 Zuco V,Benedetti V,De Cesare M,et al.Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor,RC307:enhanced DNA damage response[J].Int J Cancer,2010,126(5):1246-1255.
18 Sankunny M,Parikh RA,Lewis DW,et al.Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss[J].Genes Chromosomes Cancer,2014,53(2):129-143.
19 Lam MH,Rosen JM.Chk1 versus Cdc25:chking one's levels of cellular proliferation[J].Cell Cycle,2004,3(11):1355-1357.
20 Kohn EA,Ruth ND,Brown MK,et al.Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation[J].J Biol Chem,2002,277(29):26553-26564.
21 Levesque AA,Fanous AA,Poh A,et al.Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest[J].Mol Cancer Ther,2008,7(2):252-262.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[3]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[4]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[5]	袁桂霞, 李岩, 冯婉琪, 夏小娟, 李旭. 抑癌基因DKK2抑制儿童肾母细胞瘤细胞增殖的机制研究[J]. 实用肿瘤学杂志, 2019, 33(1): 14-20.
[6]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[7]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[8]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[9]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[10]	卞秀森, 李光, 关欣宇, 张伊, 狄畅, 马璨. UHRF1通过调控细胞自噬抑制肺腺癌细胞增殖的分子机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 498-502.
[11]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[12]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[13]	肖洪伟, 陈升, 王艳良, 苏学良. 距肛缘≤8 cm的T₁期直肠癌患者经肛门局部切除术的预后及影响因素分析[J]. 实用肿瘤学杂志, 2018, 32(6): 545-549.
[14]	刘娟综述, 张澍田审校. 细胞周期蛋白依赖性激酶抑制因子3在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 575-578.
[15]	陈鳞, 王恩湘, 刘群友, 钟鹰, 周国良, 赵喜雁. CDX2基因通过NF-κB信号通路抑制结肠癌细胞增殖[J]. 实用肿瘤学杂志, 2018, 32(5): 398-403.

Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性

Expression of Chk1 in glioblastoma and its association with tumor biological behavior and prognosis survival

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价